Clinical Trial Update: A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy [Phase 2]

View source ↗

Summary

Phase II clinical study evaluating HLX43 in patients with recurrent/metastatic esophageal squamous cell carcinoma who failed or were intolerant to standard ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• HLX43

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Esophageal Cancer | Phase 2 | Status: RECRUITING